By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Aventis Pharma S.A. et al. v. Accord Healthcare Inc. USA
1:11-cv-00018; filed January 6, 2011 in the District Court of Delaware
• Plaintiffs: Aventis Pharma S.A.; Sanofi-Aventis U.S. LLC
• Defendant: Accord Healthcare Inc. USA
Infringement of U.S. Patent Nos. 5,714,512 ("Compositions Containing Taxane Derivatives," issued February 3, 1998) and 5,750,561 (same title, issued May 12, 1998) following a Paragraph IV certification as part of Accord's filing of an ANDA to manufacture a generic version of Aventis' Taxotere® (docetaxel, used to treat breast, lung, prostate, gastric, and head and neck cancers). View the complaint here.
App Pharmaceuticals, LLC v. Navinta LLC et al.
3:11-cv-00063; filed January 6, 2011 in the District Court of New Jersey
• Plaintiff: APP Pharmaceuticals, LLC
• Defendants: Navinta LLC; Sandoz Inc.; Sandoz AG
Infringement of U.S. Patent Nos. 5,670,524 ("Methods and Compositions for the Treatment of Pain Utilizing Ropivacaine," issued September 23, 1997) and 5,834,489 (same title, issued November 10, 1998) following defendants' filing of an ANDA to manufacture a generic version of APP's Naropin® (ropivacaine hydrochloride injection product, used for the production of regional or local anesthesia for surgery and for acute pain management). View the complaint here.
Pronova BioPharma Norge AS v. Apotex Corp. et al.
1:11-cv-00012; filed January 5, 2011 in the District Court of Delaware
• Plaintiff: Pronova BioPharma Norge AS
• Defendants: Apotex Corp.; Apotex Inc.
Infringement of U.S. Patent No. 7,732,488 ("Pharmaceutical Composition Comprising Low Concentrations of Environmental Pollutants," issued June 8, 2010) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Pronova's Lovaza® (omega-3-acid ethyl esters, used to reduce triglyceride levels in adult patients with very high triglyceride levels). View the complaint here.
Comments